The latest price of Durvalumab in 2025

Durvalumab/Infinifer (Durvalumab) is a humanized monoclonal antibody that mainly targets programmed death ligand-1 (PD-L1). Its mechanism of action is to restore the body's immune surveillance function against tumor cells by blocking the binding of PD-L1 to PD-1 and CD80 receptors, thereby enhancing the anti-tumor activity of T cells. Compared with early immune checkpoint inhibitors, durvalumab is more prone to precise regulation of the immune microenvironment in its mechanism of action, making it of high research value in the treatment of various malignant tumors.

At present, durvalumab has been approved for multiple indications worldwide, including small cell lung cancer, non-small cell lung cancer, endometrial cancer, cholangiocarcinoma, liver cancer, bladder cancer, etc. Especially as maintenance treatment after radiotherapy and chemotherapy, it has been proven to significantly delay disease progression and improve patient survival rates. In China, durvalumab has been successfully marketed, but it has not yet been included in the medical insurance list. Therefore, patients have relatively high financial pressure to obtain the drug. According to public information, the common specifications of the drug in China are 120mg/2.4mL and 500mg/10mL. Each box sells for approximately RMB 4,000 to more than RMB 10,000. The specific price varies depending on the region and supply channels.

In overseas markets, the selling price of durvalumab is also at a relatively high level. For example, in the United States, its common specification is 120mg/2.4mL, and the price per box is about more than a thousand US dollars. However, due to the influence of exchange rates and medical insurance policies, the actual cost will fluctuate to a certain extent. At present, there are no generic drugs of durvalumab on the market, so patients can mainly choose the original drug version. Considering the complex production process of immunotherapy drugs, the launch of generic drugs usually takes longer, which also means that the price of durvalumab will remain at a high level for some time to come.

Reference materials:https://www.imfinzi.com/